This clinical trial is focused on studying treatments for metastatic hormone-sensitive prostate cancer, a type of prostate cancer that has spread to other parts of the body but still responds to hormone therapy. The study is comparing two different treatments. One treatment involves a medication called SHR3680, which is a non-steroidal selective androgen receptor antagonist, combined with androgen deprivation therapy (ADT). The other treatment uses a medication called Bicalutamide, also a non-steroidal antiandrogen, combined with ADT. Additionally, the study includes the use of Goserelin, which is administered as an implant and helps in reducing the levels of certain hormones in the body.

The purpose of the study is to determine if the combination of SHR3680 and ADT is more effective than the combination of Bicalutamide and ADT in improving the time patients live without the cancer getting worse, known as radiological progression-free survival, and overall survival. Participants in the study will receive one of these treatment combinations and will be monitored over a period to assess the effectiveness and safety of the treatments. The study will also look at other factors such as the time it takes for prostate-specific antigen (PSA) levels to rise, the time to the next bone-related event, and the time to the start of the next prostate cancer treatment.

Throughout the study, participants will receive regular check-ups and assessments to monitor their health and the progress of the cancer. The study aims to provide valuable information on the best treatment options for patients with this type of prostate cancer, potentially leading to improved outcomes and quality of life for those affected by the disease.